Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Benign Prostatic Hyperplasia Therapeutics Market, by Therapy
1.4.2 Europe Benign Prostatic Hyperplasia Therapeutics Market, by Therapeutics Class
1.4.3 Europe Benign Prostatic Hyperplasia Therapeutics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition and scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Benign Prostatic Hyperplasia Therapeutics Market by Therapy
3.1 Europe Mono Drug Therapy Market by Country
3.2 Europe Combination Drug Therapy Market by Country
Chapter 4. Europe Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
4.1 Europe Alpha Blockers Market by Country
4.2 Europe 5- alpha Reductase Inhibitors Market by Country
4.3 Europe Phosphodiesterase-5 Inhibitors Market by Country
4.4 Europe Others Market by Country
Chapter 5. Europe Benign Prostatic Hyperplasia Therapeutics Market by Country
5.1 Germany Benign Prostatic Hyperplasia Therapeutics Market
5.1.1 Germany Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.1.2 Germany Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.2 UK Benign Prostatic Hyperplasia Therapeutics Market
5.2.1 UK Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.2.2 UK Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.3 France Benign Prostatic Hyperplasia Therapeutics Market
5.3.1 France Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.3.2 France Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.4 Russia Benign Prostatic Hyperplasia Therapeutics Market
5.4.1 Russia Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.4.2 Russia Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.5 Spain Benign Prostatic Hyperplasia Therapeutics Market
5.5.1 Spain Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.5.2 Spain Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.6 Italy Benign Prostatic Hyperplasia Therapeutics Market
5.6.1 Italy Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.6.2 Italy Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.7 Rest of Europe Benign Prostatic Hyperplasia Therapeutics Market
5.7.1 Rest of Europe Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.7.2 Rest of Europe Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
Chapter 6. Company Profiles
6.1 GlaxoSmithKline PLC (GSK)
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.2 Astellas Pharma, Inc.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Regional Analysis
6.2.4 Research & Development Expense
6.3 Eli Lilly and Company
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Regional Analysis
6.3.4 Research & Development Expense
6.4 Allergan PLC (AbbVie)
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expense
6.5 Merck Group (Merck Sharp & Dohme Corp.)
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 Boehringer Ingelheim International Gmbh
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Regional & Segmental Analysis
6.6.4 Research & Development Expenses
6.7 Teva Pharmaceutical Industries Ltd.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expenses
6.8 Sanofi S.A.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental and Regional Analysis
6.8.4 Research & Development Expense
6.9 Pfizer, Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expense
6.10. Abbott Laboratories
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Segmental and Regional Analysis
6.10.4 Research & Development Expense
Unique Offerings 